Ekso Bionics Holdings, Inc. (EKSO)
NASDAQ (CM) NASDAQ (CM) Primary 
Ekso Bionics (EKSO) Upgraded to Buy: Here's Why
Ekso Bionics (EKSO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ekso Bionics (EKSO) Reports Q3 Loss, Beats Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to a loss of $1.5 per share a year ago.
Ekso Bionics (EKSO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Ekso Bionics (EKSO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Ekso Bionics Holdings, Inc. (EKSO) Q2 2025 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company Participants Jerome Wong - CFO & Corporate Secretary Scott G. Davis - CEO & Director Stephen Kilmer - Corporate Participant Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division Swayampakula Ramakanth - H.C.
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.2. This compares to a loss of $1.95 per share a year ago.
Ekso Bionics Holdings, Inc. (EKSO) Q1 2025 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics First Quarter 2025 Financial Results Conference Call.
Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago.
Ekso Bionics Holdings, Inc. (EKSO) Q4 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Li Chen - H.C. Wainwright Ben Haynor - Lake Street Capital Operator Greetings, and welcome to the Ekso Bionics Fourth Quarter 2024 Financial Results Conference Call.
Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.24 per share a year ago.
Ekso Bionics Holdings, Inc. (EKSO) Q3 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2024 Financial Results Call.
Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
Ekso Bionics EKSO has reached a significant milestone in terms of transforming mobility solutions, particularly for individuals with spinal cord injuries (SCI). The company recently secured initial reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton.
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Ekso Bionics (NASDAQ: EKSO ) stock is taking a beating on Tuesday following the release of the exoskeleton company's Q2 earnings report. The bad news for Ekso Bionics starts with its diluted earnings per share of -13 cents.
